Stockscreener 앱 받기
91.05
1.38%
-1.27
전일 마감가:
$92.32
열려 있는:
$93.7
하루 거래량:
335.50K
Relative Volume:
0.50
시가총액:
$4.71B
수익:
$379.25M
순이익/손실:
$-77.34M
주가수익비율:
-56.48
EPS:
-1.6122
순현금흐름:
$-27.87M
1주 성능:
+5.18%
1개월 성능:
+35.79%
6개월 성능:
+72.44%
1년 성능:
+98.67%
1일 변동 폭
$90.86
$93.70
1주일 범위
$82.00
$93.70
52주 변동 폭
$36.88
$93.70
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
91.05 | 4.77B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Dividend Watch: Will Mirum Pharmaceuticals Inc benefit from AI trendsJuly 2025 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Treasury Yields: Is Rush Enterprises Inc stock overvalued or fairly priced2025 Market Overview & Daily Volume Surge Signals - baoquankhu1.vn
Mirum Stock Rises 7% in a Week: Here's What You Should Know - TradingView — Track All Markets
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Mirum Pharmaceuticals stock hits all-time high at 91.99 USD By Investing.com - Investing.com India
Mirum Pharmaceuticals stock hits all-time high at 91.99 USD - Investing.com
HC Wainwright Has Bullish Estimate for MIRM FY2025 Earnings - MarketBeat
Citizens reiterates Market Outperform rating on Mirum Pharmaceuticals stock By Investing.com - Investing.com UK
Income Plays: How correlated is MSPRK to the S P500July 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
MIRM: Four pivotal clinical readouts and robust revenue growth position the pipeline for major expansion - TradingView — Track All Markets
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM) - FinancialContent
Aug Highlights: Is Mirum Pharmaceuticals Inc 08D stock undervalued after correctionQuarterly Market Summary & Weekly High Return Stock Forecasts - Bộ Nội Vụ
3 Top Growth Stocks to Buy in the First Half of 2026 - Finviz
Mirum Pharmaceuticals, Inc. (MIRM) Investor Outlook: Promising Upside with 47.2% Revenue Growth - DirectorsTalk Interviews
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Baird raises Mirum Pharmaceuticals stock price target to $95 on strong sales - Investing.com Canada
Mirum Pharmaceuticals reports $520 million in 2025 net product sales By Investing.com - Investing.com Nigeria
Baird Adjusts Mirum Pharmaceuticals Price Target to $95 From $88, Maintains Outperform Rating - marketscreener.com
Mirum Pharmaceuticals stock exceeds FY25 guidance, TD Cowen reiterates Buy By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock exceeds FY25 guidance, TD Cowen reiterates Buy - Investing.com Nigeria
Mirum Pharmaceuticals announces preliminary unaudited 2025 results, demonstrating strong commercial growth and pipeline momentum - marketscreener.com
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum - TradingView — Track All Markets
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum - FinancialContent
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - marketscreener.com
Will strong Livmarli uptake continue to aid MIRM's revenues in 2026? - MSN
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price Is Right But Growth Is Lacking After Shares Rocket 34% - 富途牛牛
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug - Investing.com Nigeria
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Update & High Conviction Buy Zone Alerts - Улправда
MarketsMedicine Hat News - FinancialContent
Can Mirum Pharmaceuticals Inc. (08D) stock test all time highsTrade Performance Summary & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. (08D) stock undervalued after correctionJuly 2025 Institutional & Risk Managed Investment Entry Signals - Улправда
Will Mirum Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Stock Report & Risk Controlled Daily Plans - Улправда
How supply chain issues affect Mirum Pharmaceuticals Inc. stockJuly 2025 Action & Fast Gaining Stock Reports - Улправда
Can Mirum Pharmaceuticals Inc. stock reach $100 price targetQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD By Investing.com - Investing.com Nigeria
How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight - Yahoo Finance
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsInstitutional Holding Changes & High Return Investment Plans - Улправда
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - FinancialContent
How Mirum Pharmaceuticals Inc. stock compares to growth peersMorning Star Patterns & Free Skyrocketing Profit Margins - Улправда
Should you invest in Mirum Pharmaceuticals (MIRM)? - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 12-Month HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD - Investing.com India
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockEarnings Date Calendar & Low Cost Trading Plans - ulpravda.ru
Mirum Pharmaceuticals (MIRM) price target increased by 16.25% to 104.35 - MSN
Should You Invest in Mirum Pharmaceuticals (MIRM)? - Finviz
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):